HealthQuill US
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients 18 years or older, to the treatment regime.
Drugs Health Pharma

Regulator okays Insulet’s insulin pump in US to treat type 2 diabetes

Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.

Read More
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Health Pharma

J&J plans to acquire Israel’s V-Wave by paying $600 million upfront

Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the.

Read More
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.
Drugs Health Pharma

AstraZeneca’s asthma drug gets regulator’s approval in China

China’s drug regulator, the National Medical Products Association, has approved  AstraZeneca Plc’s asthma drug.

Read More
Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.
Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance 

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.

Read More
https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
Drugs Health Pharma

Daiichi Sankyo to pay Merck $170 million for cancer test drug rights

Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.

Read More
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested in mice, according to researchers at the Washington University School of Medicine in St. Louis.
Drugs Health Pharma

Scientists develop potential compound to neutralise flesh-eating bacteria

A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested.

Read More
A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the current guidelines for cholesterol and high blood pressure treatment remain the same, according to a Harvard Medical School study.
Drugs Health Pharma

New cardiovascular risk calculator may impose a burden on 16 million US citizens

HQ Team August 6, 2024: A new cardiovascular disease risk calculator may render 16 million US citizens ineligible for preventive therapy if the.

Read More
Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.
Drugs Health Pharma

GenX faces a higher risk of 17 cancer types than older generation

Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.

Read More
WHO issues global warning on drug-resistant Klebsiella Pneumonie pathogen
Drugs Health Pharma

WHO warns on drug-resistant Klebsiella Pneumonie spread

HQ Team August 4, 2024: The WHO has warned about the rising global incidence of hypervirulent and multi-resistant Klebsiella Pneumoniae (hvKp) infections. The.

Read More